Last reviewed · How we verify
NCT04201340
Topcon DRI OCT Triton With SS-OCT Angio Software Evaluation Study
trial testing DRI OCT Triton with SS-OCT Angio software in Fluorescein Angiography Imaging in 211 participants. Completed in 20 October 2022.
28 July 2022
Quick facts
| Lead sponsor | Topcon Corporation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 211 |
| Start date | 11 December 2019 |
| Primary completion | 28 July 2022 |
| Estimated completion | 20 October 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- DRI OCT Triton with SS-OCT Angio software
- Cirrus HD-OCT 5000
- TRC-50DX
Conditions studied
- Fluorescein Angiography Imaging — all drugs for Fluorescein Angiography Imaging →
Sponsor
Topcon Corporation
Who can join
22 and older, any sex, with Fluorescein Angiography Imaging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Comparisons for vascular structure visualization in the retina and choroid.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04201340
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Topcon Corporation trials
Trials by the same sponsor.
- NCT06733428 — Agreement and Precision Study · completed
- NCT06250868 — TRK-3 Performance of Pachymetry · completed
- NCT06247072 — TRK-3 Conformance to Standards for Tonometers · completed
- NCT06135727 — Screening Protocol · terminated
- NCT05286502 — NW500 Non-Mydriatic Retinal Camera Clinical Performance Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04201340 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Topcon Corporation
- Last refreshed: 8 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04201340.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing